News

Announcing the launch of the first-ever tool in life sciences and health care to evaluate and rank new technologies and services via an end-user process. The Signature Award,

The technology helps to solve the age-old problem of supplement bioavailability. Response Scientific CEO Gregg Webster noted the reality is that some of the most promising dietary supplements

DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation. In patients

Regpara acts on calcium receptors on the parathyroid gland to suppress the secretion of parathyroid hormone (PTH). The drug was approved in Japan for secondary HPT in patients

Boulder, Colo-based Array BioPharma focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer. The scope of the Dynamics AX project

The objective of the Phase III study (PRESERVE-1) is to assess whether ATryn may safely prolong pregnancy in mothers with very early preterm preeclampsia and consequently decrease prematurity-associated

The breakthrough therapy designation is based on data from the company’s ongoing Phase III clinical trial program that is evaluating the all-oral combination regimen of DCV, an investigational

DuoResp Spiromax is indicated for the treatment of COPD patients when a combination inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate. The CHMP decision creates a path forward

Provided under the 2012 US Generating Antibiotic Incentives Now (GAIN) Act, the QIDP designation allows the company to have priority review, eligibility for fast-track status, and an additional